# Kv1.3 channel blocker

Type: Technology

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/kv13-channel-blocker
Canonical HTML page: https://getbiobrief.com/entity/kv13-channel-blocker

## Recent coverage (1 stories)

### Zealand Pharma Advances Oral Kv1.3 Blocker ZP9830 After Positive Phase 1a
2026-02-19 13:01:48 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Zealand Pharma has announced positive topline results from its Phase 1a trial of ZP9830, a novel Kv1.3 channel blocker. The study successfully met its primary objectives for safety and tolerability, paving the way for further development of this oral candidate for chronic inflammatory and autoimmune diseases.
Full story: https://getbiobrief.com/story/zealand-pharma-zp9830-phase-1a-results

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.